Family urges NHS to approve zanidatamab for aggressive bile duct cancer

In Brief

Family calls on NHS to approve zanidatamab after tumours shrank in bile duct cancer patient.

Key Facts

• Huw Jones died in February after suffering from bile duct cancer
• Jones's family credit zanidatamab with enabling them to spend a year together
• Zanidatamab is a new treatment shown to shrink tumours in aggressive cancer
• The family is urging the NHS to approve zanidatamab for wider patient access
• The treatment could offer patients a chance at a more normal life

What Happened

Huw Jones, who had bile duct cancer, passed away in February. His family stated that zanidatamab helped shrink his tumours and allowed them to spend an additional year together. They are now urging the NHS to approve the treatment for broader use.

Why It Matters

Approval of zanidatamab by the NHS could provide a new treatment option for patients with aggressive bile duct cancer, potentially improving survival and quality of life.

What's Next

The NHS will consider the approval of zanidatamab, and stakeholders will watch for decisions on its availability for patients with aggressive cancers.